Pharmaceutical

CymaBay maps out regulatory filing for primary biliary cholangitis drug seladelpar

Regulatory applications in EU and the UK will follow a potential filing in the US in early 2024.

Sep 21, 2023 - 20:00
CymaBay maps out regulatory filing for primary biliary cholangitis drug seladelpar
Regulatory applications in EU and the UK will follow a potential filing in the US in early 2024.
Read the original article

Tags:

Previous Article

Evaxion partners with Afrigen Biologics to develop mRNA gonorrhea vaccine

Next Article

GSK’s Ojjaara receives FDA approval for treating myelofibrosis patients with ana...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Rocket Pharmaceuticals’ RP-A601 receives FDA designations

Rocket Pharmaceuticals’ RP-A601 receives FDA designations

Jun 9, 2023

STAT+: Pharmalittle: Pharma hopes reformulated drugs will skirt Medicare negotiations; Biogen to acquire Reata for $7.3 billion

STAT+: Pharmalittle: Pharma hopes reformulated drugs wi...

Jul 28, 2023

WestGene wins FDA nod to study mRNA vaccine to treat certain cancers

WestGene wins FDA nod to study mRNA vaccine to treat ce...

May 11, 2024